[Webinar] Canada: The New Frontier For U.S. IP Owners - December 4th, 12:00pm ET

Smart & Biggar

Smart & Biggar

Date: Tuesday December 4, 2018
Time: 12 PM EDT | 9 AM PT

Please click here to register


Canada is increasingly becoming a hot bed for IP litigation involving U.S. IP owners, and provides a highly favourable forum from a procedural, substantive law and litigation costs perspective.

American companies have seen record-setting damages of more than 1/2 billion dollars, pro-plaintiff decisions, and precedent-setting appeals before the Supreme Court in Canada. With improved court procedures, U.S. litigants are also getting to trial more efficiently and obtaining pre-trial remedies more readily in Canada as compared to other jurisdictions.

Learn how U.S. IP owners are benefitting from Canadian IP litigation strategies, and explore how recent developments 'north of the border' have helped American companies find success through the courts in Canada. 

Discussion Topics:

  • Top differences between U.S. and Canadian patent litigation
  • The new Canadian patent landscape for pharma/biologic innovators
  • New procedures for faster, cheaper trademark litigation in Canada
  • How to win in Canadian copyright, design and media piracy cases

Speakers & Discussion Topics

Moderated by: Jeremy Want, Partner
Practice Head, Litigation

Patents - Steven Garland, Managing Partner

Successful lead counsel in Dow v. Nova — Canada’s largest accounting of defendant’s profits award in respect of revenues of approximately $1B dollars. Ranked for IP Litigation in Chambers & Partners, named Canada’s IP Lawyer of the Year (Best Lawyers).

Discussion topics:

  • Top differences between U.S. and Canadian patent litigation
  • Leveraging the advantages of the Canadian system
  • Strategies for winning at trial
  • Financial benefits of an accounting of profits

Pharma & Life Sciences - Yoon Kang, Partner

Co-counsel in the successful Supreme Court of Canada appeal in AstraZeneca v. Apotex. Recognized as a "Life Science Star" by LMG Life Sciences, a "Litigation Star" by Benchmark, and by Euromoney as one of the Top 250 Women in Business Law.

Discussion topics:

The new patent landscape for pharma/biologic innovators:

  • The end of the Promise Doctrine of utility
  • New litigation regime - no more"dual litigation"
  • Patent term extension now available in Canada (CSPs)

Trademarks - Mark Evans, Partner

Successful trial counsel in numerous trademark cases. Twice Selected as Canada’s Trademark Litigator of the Year (Benchmark), Gold ranking in WTR1000 for enforcement & litigation.

Discussion topics:

  • Strategies for succeeding in Canadian trademark litigation
  • New procedures for faster, cheaper trademark litigation in Canada
  • The impact of upcoming amendments to Canada’s Trademarks Act

Copyrights & Design - François Guay, Partner

Successful trial counsel in numerous copyright and design cases. Twice selected as Canada’s Trademark Litigator of the Year (Benchmark), ranked by Chambers & Partners for IP Litigation.

Discussion topics:

  • Extraordinary remedies in Canada - search and seizure orders and pre-trial injunctive relief
  • How to win in Canadian copyright, design and piracy cases - online streaming to consumer products to architectural works

Please click here to register


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Smart & Biggar | Attorney Advertising

Written by:

Smart & Biggar

Smart & Biggar on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.